Amitabh Kant Bharadwaj, MD
Ophthalmology · Pinole
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 8
- 1 carrier
- Offices
- 2
- Since medical school
- 25 years
- Harvard Medical School, 2001
Offices
2 locations
Hospitals listed: Alta Bates Summit Medical Center - Alta Bates Camp · California Pacific Medical Center- Van Ness Campus. That is not proof they admit you there this week.
Plans that list them
8 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Bharadwaj’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A101201 · Current
Licensed to practise in California · since 2007 · expires 2028-11-30 · Harvard Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Ophthalmology - Ophthalmology
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Alta Bates Summit Medical Center - Alta Bates CampBerkeley, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.298, Oct 2024 – Sep 2025
- California Pacific Medical Center- Van Ness CampusSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.224, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.325, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.373, Oct 2024 – Sep 2025
See every measure and the patient survey for Alta Bates Summit Medical Center - Alta Bates Camp
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 6 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.298 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.18 (0.16 to 2.2) · 730 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.51 to 1.23) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 188.12 (132.31 to 243.94) · 50 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 50 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 189 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.6 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 103 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 1,585 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 3,929 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.11 to 0.51) · 3,954 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.15 (0.95 to 5.36) · 754 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.62 (0 to 3.33) · 325 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.99 (0.39 to 3.59) · 717 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.85 (2.27 to 19.44) · 326 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.79 (1.08 to 8.49) · 302 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.68 (0.19 to 3.18) · 184 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.17 (0 to 0.88) · 3,240 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 161 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.207 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.48 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.785 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.4 · 243 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -58.2 · 194 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -12.3 · 177 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 209 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.8 to 7.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.2 (9.4 to 15.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.8 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.2 · 81 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (10 to 18.1) · 315 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.2) · 137 cases | No different | Jan 2024 – Dec 2024 |
What patients said (449 patients answered, 15% of those asked)
| Cleanliness | 2 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 62% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 53% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 58% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 38% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
See every measure and the patient survey for California Pacific Medical Center- Van Ness Campus
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.224 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.325 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.373 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.14 (0.3 to 1.97) · 2,271 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.81 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.86 (151.51 to 234.22) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.3 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.5 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 356 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.3 · 259 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 173 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,316 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.49) · 6,430 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.09 to 0.47) · 7,168 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.3 (1.5 to 5.09) · 2,196 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.47 (1.21 to 3.74) · 925 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.63 (1.37 to 3.88) · 1,954 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.13 (6.06 to 14.2) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.26 (4.67 to 9.85) · 1,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.31 to 3.03) · 832 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.33 (0 to 0.85) · 5,406 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.443 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.717 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 200 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 449 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8.7 · 418 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.1 · 260 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.2 · 293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.6 to 7.6) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (7.7 to 13.5) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 11 · 33 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 66 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.4 to 16.7) · 551 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 219 cases | No different | Jan 2024 – Dec 2024 |
What patients said (478 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$1,831,459
Medicare paid this office $1,831,459 for 621 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, aflibercept, 1 mg | 146 | $1,092,426 | None |
| Injection, aflibercept hd, 1 mg | 24 | $199,300 | None |
| Injection of drug into eye | 208 | $135,162 | $120 |
| Injection, faricimab-svoa, 0.1 mg | 11 | $74,976 | None |
| Imaging of retina | 608 | $73,223 | $40 |
See all 14 services
| Injection, aflibercept, 1 mg | 146 | $1,092,426 | None |
| Injection, aflibercept hd, 1 mg | 24 | $199,300 | None |
| Injection of drug into eye | 208 | $135,162 | $120 |
| Injection, faricimab-svoa, 0.1 mg | 11 | $74,976 | None |
| Imaging of retina | 608 | $73,223 | $40 |
| Unclassified biologics | 13 | $65,712 | None |
| Established patient problem focused exam of visual system | 388 | $58,538 | $88 |
| Injection, bevacizumab, 10 mg | 54 | $16,660 | None |
| Established patient complete exam of visual system | 121 | $15,543 | $120 |
| New patient complete exam of visual system | 105 | $14,591 | $139 |
| Removal of eye fluid (vitreous) between lens and retina | 12 | $9,825 | $819 |
| New patient visit (45+ min) | 63 | $9,771 | $155 |
| New patient visit (60+ min) | 32 | $6,631 | $207 |
| Photography of the retina | 11 | $405 | $37 |
Procedures Medicare counted
| Cataract surgery | 1-10 | None |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Injection of drug into eye | 511 | 481 | 706 | 922 | 836 | 1,123 |
| Photocoagulation treatment to prevent detachment of retina | – | – | – | 17 | – | – |
| Removal of eye fluid (vitreous) between lens and retina | – | – | – | – | – | 12 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
621 Original Medicare patients in 2024. Average age 78 · Under 65 2% · 85 and older 22% · Women 59% · Also on Medicaid 16% · Health risk score 1.29. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 70% · Diabetes 27% · Coronary heart disease 21% · Chronic kidney disease 21% · Cancer 18% · Atrial fibrillation 17% · Depression 16% · Heart failure 12% · COPD 10% · Stroke 8% · Dementia 7%.
The office billed $5,083,530, Medicare allowed $2,304,036 and paid $1,831,459; for 9,681 services of 39 kinds; $1,407,085 of it was for drugs given in the office and $424,374 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 621 | 9,681 | 78 | 1.29 | $5,083,530 | $1,831,459 |
| 2023 | 518 | 8,118 | 77 | 1.24 | $3,088,288 | $1,151,541 |
| 2022 | 506 | 5,867 | 76 | 1.17 | $2,805,096 | $1,164,241 |
| 2021 | 408 | 3,791 | 75 | 1.19 | $1,822,085 | $880,288 |
| 2020 | 298 | 2,490 | 74 | 1.26 | $1,097,750 | $541,059 |
| 2019 | 308 | 2,684 | 74 | 1.39 | $1,166,055 | $546,591 |
| 2018 | 205 | 1,600 | 75 | 1.43 | $411,200 | $179,773 |
| 2017 | 106 | 814 | 71 | 1.69 | $176,705 | $69,747 |
| 2016 | 87 | 770 | 71 | 1.28 | $167,025 | $64,869 |
| 2015 | 35 | 232 | 71 | 1.78 | $55,095 | $21,969 |
| 2014 | 14 | 211 | 73 | 1.75 | $49,400 | $19,193 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Injection, aflibercept, 1 mg | 100 | $727,809 | None |
| Injection of drug into eye | 161 | $96,425 | $115 |
| Imaging of retina | 508 | $55,339 | $39 |
| Established patient problem focused exam of visual system | 289 | $41,260 | $87 |
| New patient complete exam of visual system | 139 | $19,554 | $141 |
| Injection, bevacizumab, 10 mg | 60 | $16,925 | None |
| Established patient complete exam of visual system | 86 | $10,697 | $123 |
| New patient visit (45+ min) | 36 | $5,415 | $150 |
| New patient visit (60+ min) | 20 | $4,070 | $204 |
| 2d ultrasound scan of eye tissue and structures | 13 | $853 | $47 |
2022: 11 services
| Injection, aflibercept, 1 mg | 89 | $837,651 | None |
| Injection of drug into eye | 160 | $99,286 | $108 |
| Imaging of retina | 478 | $54,486 | $36 |
| Established patient problem focused exam of visual system | 281 | $35,220 | $76 |
| Injection, bevacizumab, 10 mg | 89 | $21,576 | None |
| New patient complete exam of visual system | 167 | $21,186 | $127 |
| Established patient complete exam of visual system | 74 | $8,920 | $119 |
| New patient visit (45+ min) | 32 | $4,668 | $146 |
| Photocoagulation treatment to prevent detachment of retina | 14 | $3,895 | $229 |
| New patient visit (60+ min) | 12 | $2,437 | $203 |
| Photography of the retina | 11 | $404 | $37 |
2021: 7 services
| Injection, aflibercept, 1 mg | 82 | $660,046 | None |
| Injection of drug into eye | 132 | $76,101 | $108 |
| Imaging of retina | 391 | $44,169 | $37 |
| Established patient problem focused exam of visual system | 219 | $29,615 | $78 |
| New patient complete exam of visual system | 177 | $21,611 | $122 |
| Injection, bevacizumab, 10 mg | 76 | $17,381 | None |
| Established patient complete exam of visual system | 27 | $3,357 | $120 |
2020: 6 services
| Injection, aflibercept, 1 mg | 50 | $391,951 | None |
| Injection of drug into eye | 97 | $43,680 | $91 |
| Imaging of retina | 292 | $28,477 | $36 |
| Established patient problem focused exam of visual system | 167 | $19,161 | $72 |
| New patient complete exam of visual system | 123 | $15,265 | $124 |
| Injection, bevacizumab, 10 mg | 56 | $12,223 | None |
2019: 8 services
| Injection, aflibercept, 1 mg | 49 | $354,056 | None |
| Injection of drug into eye | 84 | $45,795 | $90 |
| Imaging of retina | 297 | $31,073 | $37 |
| Established patient problem focused exam of visual system | 158 | $24,787 | $77 |
| New patient complete exam of visual system | 169 | $21,302 | $126 |
| Injection, bevacizumab, 10 mg | 60 | $14,034 | None |
| Established patient complete exam of visual system | 29 | $3,417 | $110 |
| Exam of the internal drainage system of eye | 11 | $677 | $25 |
2018: 8 services
| Injection, aflibercept, 1 mg | 11 | $43,997 | None |
| Injection of drug into eye | 56 | $23,153 | $92 |
| Imaging of retina | 183 | $19,662 | $39 |
| Established patient complete exam of visual system | 95 | $19,612 | $110 |
| New patient complete exam of visual system | 128 | $17,133 | $134 |
| Established patient problem focused exam of visual system | 86 | $14,634 | $78 |
| Injection, bevacizumab, 10 mg | 53 | $13,049 | None |
| Photocoagulation treatment to prevent detachment of retina | 12 | $6,864 | $490 |
2017: 6 services
| Established patient complete exam of visual system | 62 | $11,615 | $105 |
| Injection of drug into eye | 31 | $11,341 | $86 |
| Imaging of retina | 95 | $7,901 | $35 |
| Injection, bevacizumab, 10 mg | 30 | $7,233 | None |
| New patient complete exam of visual system | 51 | $6,412 | $126 |
| Established patient problem focused exam of visual system | 33 | $6,059 | $67 |
2016: 8 services
| Established patient complete exam of visual system | 48 | $17,534 | $108 |
| Injection of drug into eye | 27 | $9,796 | $90 |
| Imaging of retina | 77 | $7,982 | $41 |
| New patient complete exam of visual system | 58 | $6,754 | $116 |
| Compounded drug, not otherwise classified | 26 | $5,842 | None |
| Established patient problem focused exam of visual system | 25 | $3,091 | $77 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 11 | $2,115 | $96 |
| Photography of the retina | 15 | $994 | $66 |
2015: 4 services
| Established patient complete exam of visual system | 18 | $6,268 | $110 |
| Injection of drug into eye | 13 | $4,176 | $89 |
| Imaging of retina | 23 | $2,422 | $40 |
| New patient complete exam of visual system | 16 | $1,973 | $123 |
2014: 1 service
| Imaging of retina | 12 | $1,844 | $42 |
Medicaid work
$61,292 in 2024
Medicaid paid $61,292 for 659 billed services this clinician did in 2024, up to 51 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 221 | $26,196 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 347 | $17,715 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 91 | $17,381 |
| 2024 | 659 | 3 | 51 | $61,292 |
| 2023 | 1,132 | 6 | 65 | $116,591 |
| 2022 | 1,198 | 6 | 71 | $147,715 |
| 2021 | 864 | 5 | 51 | $60,368 |
| 2020 | 478 | 4 | 38 | $23,070 |
| 2019 | 773 | 6 | 56 | $43,816 |
| 2018 | 611 | 6 | 37 | $39,561 |
See the largest Medicaid services in earlier years
2023
| Intravitreal injection of a pharmacologic agent (separate procedure) | 230 | $35,450 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 300 | $32,896 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 555 | $24,968 |
| Aflibercept injection | 13 | $18,992 |
| OPH SVCS MEDICAL XM&EVAL COMPRE NEW PT 1/> VST | 15 | $2,591 |
| Injection, bevacizumab, 10 mg | 19 | $1,694 |
2022
| Aflibercept injection | 43 | $63,915 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 235 | $27,177 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 274 | $26,011 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 579 | $24,696 |
| OPH SVCS MEDICAL XM&EVAL COMPRE NEW PT 1/> VST | 29 | $4,481 |
| Injection, bevacizumab, 10 mg | 38 | $1,435 |
2021
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 494 | $22,008 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 153 | $16,613 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 156 | $14,291 |
| OPH SVCS MEDICAL XM&EVAL COMPRE NEW PT 1/> VST | 33 | $4,862 |
| Injection, bevacizumab, 10 mg | 28 | $2,595 |
2020
| Intravitreal injection of a pharmacologic agent (separate procedure) | 100 | $8,102 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 290 | $7,492 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 72 | $5,752 |
| Injection, bevacizumab, 10 mg | 16 | $1,724 |
2019
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 173 | $13,481 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 411 | $8,733 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 84 | $8,143 |
| OPH SVCS MEDICAL XM&EVAL COMPRE NEW PT 1/> VST | 51 | $7,685 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 27 | $3,831 |
| Injection, bevacizumab, 10 mg | 27 | $1,943 |
2018
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 145 | $19,563 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 332 | $7,783 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 60 | $6,226 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 30 | $2,370 |
| Injection, bevacizumab, 10 mg | 30 | $2,250 |
| OPH SVCS MEDICAL XM&EVAL COMPRE NEW PT 1/> VST | 14 | $1,369 |
Drugs they prescribed that Part D paid
$12,130
Pharmacies billed $12,130 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 344) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
229 generic and 115 brand-name prescriptions · $12,130 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Prednisolone Acetate | 54 | $3,491 | $65 |
| Atropine Sulfate | 35 | $2,777 | $79 |
| Brimonidine | 19 | $1,234 | $65 |
| Ofloxacin | 72 | $1,096 | $15 |
| Dorzolamide-Timolol | 49 | $985 | $20 |
See all 7 drugs
| Prednisolone Acetate | 54 | $3,491 | $65 |
| Atropine Sulfate | 35 | $2,777 | $79 |
| Brimonidine | 19 | $1,234 | $65 |
| Ofloxacin | 72 | $1,096 | $15 |
| Dorzolamide-Timolol | 49 | $985 | $20 |
| Latanoprost | 50 | $198 | $4 |
| Acetazolamide | 12 | $167 | $14 |
Year by year
| 2024 | 344 | 106 | 0% (0) | 33% | $12,130 |
| 2023 | 264 | 92 | 0% (0) | 28% | $14,034 |
| 2022 | 152 | 52 | 0% (0) | 32% | $8,833 |
| 2021 | 157 | 47 | 0% (0) | 46% | $7,842 |
| 2020 | 165 | 50 | 0% (0) | 44% | $11,665 |
| 2019 | 191 | 41 | 0% (0) | 60% | $13,134 |
| 2018 | 77 | 28 | 0% (0) | 62% | $6,201 |
| 2017 | 40 | 11 | 0% (0) | 55% | $1,293 |
| 2016 | 19 | None | 0% (0) | None | $505 |
| 2015 | 19 | None | 0% (0) | None | $708 |
| 2014 | 33 | 19 | 0% (0) | None | $765 |
| 2013 | 19 | None | None | None | $896 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 6 drugs
| Prednisolone Acetate | 38 | $3,144 | $83 |
| Atropine Sulfate | 20 | $1,742 | $87 |
| Dorzolamide-Timolol | 43 | $1,674 | $39 |
| Ofloxacin | 66 | $1,629 | $25 |
| Brimonidine | 21 | $335 | $16 |
| Latanoprost | 27 | $331 | $12 |
2022: 5 drugs
| Dorzolamide-Timolol | 26 | $1,355 | $52 |
| Atropine Sulfate | 20 | $1,252 | $63 |
| Prednisolone Acetate | 27 | $1,245 | $46 |
| Ofloxacin | 17 | $247 | $15 |
| Latanoprost | 13 | $220 | $17 |
2021: 6 drugs
| Prednisolone Acetate | 25 | $1,855 | $74 |
| Atropine Sulfate | 11 | $1,555 | $141 |
| Latanoprost | 30 | $938 | $31 |
| Dorzolamide-Timolol | 16 | $516 | $32 |
| Brimonidine | 17 | $311 | $18 |
| Ofloxacin | 16 | $226 | $14 |
2020: 4 drugs
| Prednisolone Acetate | 36 | $2,233 | $62 |
| Dorzolamide-Timolol | 17 | $1,024 | $60 |
| Latanoprost | 25 | $562 | $22 |
| Brimonidine | 17 | $269 | $16 |
2019: 5 drugs
| Prednisolone Acetate | 38 | $2,837 | $75 |
| Brimonidine | 20 | $2,566 | $128 |
| Atropine Sulfate | 32 | $2,340 | $73 |
| Combigan | 11 | $1,908 | $173 |
| Latanoprost | 30 | $377 | $13 |
2018: 3 drugs
| Prednisolone Acetate | 14 | $1,407 | $101 |
| Ketorolac Tromethamine | 12 | $609 | $51 |
| Ofloxacin | 11 | $179 | $16 |
2014: 2 drugs
| Gavilyte-C | 11 | $187 | $17 |
| Ofloxacin | 11 | $134 | $12 |
Money from drug and device companies
$26 in 2024
| 2024 | 1 | 1 | None | $26 |
| 2023 | 1 | 1 | None | $17 |
| 2022 | 2 | 2 | None | $63 |
| 2020 | 2 | 2 | None | $32 |
| 2019 | 1 | 1 | None | $23 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Regeneron Pharmaceuticals | Eylea Hd | $26 | 1 payment
|
See the published payment
| Regeneron Pharmaceuticals | Meals · 2024-10-11 | Eylea Hd | $26 |
See earlier years (2023, 2022, 2020, 2019)
2023: $17
| Apellis Pharmaceuticals | Syfovre | $17 | 1 payment
|
2022: $63
| Genentech USA | Vabysmo | $35 | 1 payment
|
| Abbvie | Ozurdex | $28 | 1 payment
|
2020: $32
| Carl Zeiss Meditec AG | None Specified | $19 | 1 payment
|
| Novartis Pharmaceuticals | Beovu | $13 | 1 payment
|
2019: $23
| Novartis Pharmaceuticals | None | $23 | 1 payment
|
Checkups this office reported
7 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 77.3 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Asked about smokingPatients asked about tobacco, with help to quit if they smoke | 40%That's less than half. | 425 |
| Breast cancer screeningEligible women who got a mammogram | 0%That's few of the people this applied to. | 24 |
| Diabetes eye examPeople with diabetes who got a retinal eye exam | 97%That's most of the people this applied to. | 256 |
| Diabetes poorly controlledPeople with diabetes whose blood sugar stayed very high | 100%That's most of the people this applied to. Worse on this measure. | 20 |
| Medications listed in the chartVisits where the current medication list was documented | 50%That's more than half. | 1,797 |
| Primary Open-Angle Glaucoma (POAG): Optic Nerve EvaluationAs Medicare defines this measure | 0% | 65 |
| Risky medications in older adultsOlder patients given a medication that is risky at their age | 0%That's few of the people this applied to. Better on this measure. | 610 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Implementation of medication management practice improvements
- Improved the patient portal
- Lets patients read their visit notes
- Uses standard treatment protocols
Professional record
- NPI
- 1477511806
- Licence
- CA A101201California A101201: Current · expires 2028-11-30
- Trained
- Harvard Medical School, 2001 · 25 years ago
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Medicaid ID
- NJ 001976049
- Taxonomy
- Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 1320 Tara Hills Dr Ste H, Pinole, CA, 94564
- NPI first listed
- 2006-05-03
- NPI last updated
- 2013-06-03
This is when the NPI record was last certified, not a medical board exam.